ArticleJournal of asthma and allergy2026
Differences in Type 2 Phenotype and Clinical Characteristics of Adult Asthma Patients with Different Severity, Across GINA Step 1 to 5 Asthma.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence and clinical characteristics of asthma phenotypes are less studied in mild asthma than in severe asthma. This study aims to assess the prevalence and clinical features of different phenotypes in patients with asthma with different severity. Methods: A cross-sectional study was conducted in Hong Kong. Adult patients with mild, moderate and severe asthma based on GINA steps (1 to 5) were included. The prevalence of eosinophil phenotype, elevated IgE, overlapping eosinophil phenotype with elevated IgE levels and type 2 phenotype in mild and moderate/severe asthma were compared. The clinical features of different phenotypes in patients with mild or moderate/severe asthma were also compared. Results: A total of 152 patients were recruited. The mild asthma group had significantly fewer patients with type 2 phenotype (49.0% vs 69.3%, p = 0.015), eosinophilic phenotype (25.5% vs 43.6%, p = 0.030), elevated IgE (41.2% vs 59.4%, p = 0.033), and overlapping eosinophilic phenotype with elevated IgE (17.6% vs 33.7%, p = 0.038). Those with mild eosinophilic phenotype had better lung function than their non-eosinophilic counterparts (2.67 ± 0.75 L vs 2.18 ± 0.62 L, p = 0.045), in contrast to the comparatively poorer lung function of those with eosinophilic moderate/severe asthma (87.87 ± 19.54% vs 98.10 ± 19.77%, p = 0.018). The eosinophilic phenotype and a higher blood eosinophil count were only associated with an increased risk of exacerbation in moderate/severe asthma. Conclusion: The prevalence of the type 2 phenotype is lower in patients with mild asthma than in patients with moderate/severe asthma. Eosinophilic phenotype in the mild and moderate/severe asthma group showed differences in spirometry findings and exacerbation risks. The heterogeneity in the phenotype across asthma of different severity suggests that risk stratification based on blood-based biomarkers alone may be inadequate and other clinical factors should also be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.